The global Cancer Biologics Market is valued at USD 106.2 Billion in 2023 and is projected to reach a value of USD 161.4 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 8.50% between 2024 and 2032.

Key Highlights of Cancer Biologics Market

• By Region, North America dominated the market in 2023, gaining the major market share above 38.7%
• The Asia Pacific market is expected to grow significantly from 2024 to 2032
• The US Cancer Biologics market, with a valuation of USD 30.27 billion in 2023, is projected to increase to approximately 49.81 billion by 2032
• By Applications, the Blood Cancer segment captures the highest market share of 26.7% in 2023
• On the basis of the Drug Class, the Monoclonal Antibodies category accounted for about 32.5% of the market share in 2023
• Based on End use, the Hospitals category accounted for the market share of about 61.1% in 2023
• The global Cancer Biologics market is experiencing remarkable growth due to rising demand for innovative treatments and biotechnology advancements.

{{bar_graph}}

Cancer Biologics Market: Regional Overview

The North America Cancer Biologics market exhibited substantial dominance in 2023, capturing 38.7% of the revenue share. This growth is driven by a rising incidence of cancer, influenced by lifestyle factors like smoking. The American Cancer Society estimates 1,958,310 new cancer cases and 609,820 deaths in the U.S. for 2023. North Americas advanced healthcare infrastructure and strict regulations support market growth. Government initiatives and increased R&D in Cancer Biologics are fostering innovation, particularly in fully humanized monoclonal antibodies. Additionally, a robust presence of pharmaceutical and biotechnology companies enhances market expansion. Notably, biologics are used to treat approximately 70% of breast cancer and 55% of colorectal cancer cases.

U.S. Cancer Biologics Market Overview

The Cancer Biologics market in the U.S., with a valuation of USD 30.27 Billion in 2023, is projected to reach around USD 49.81 Billion by 2032. This forecast indicates a substantial Compound Annual Growth Rate (CAGR) of 5.69 % from 2024 to 2032. The rising incidence of cancer in the U.S. is driving the market for Cancer Biologics. Breast cancer, esophageal cancer, pancreatic cancer, and gynecological cancers are becoming more common, along with rare cancers like neuroblastoma. The CDC reports about 237,000 cases of breast cancer in women and 2,100 in men annually, while the NIH estimates 650 children are diagnosed with neuroblastoma each year. Accelerated FDA approvals and reimbursement programs, such as Medicare Part B covering UNITUXIN for neuroblastoma, are fueling market growth. Support from organizations like the American Cancer Society and the American Breast Cancer Foundation is also contributing to the markets expansion. These factors are expected to drive significant growth in the U.S. Cancer Biologics market.

{{CountryImage}}

The global Cancer Biologics market can be categorized as Drug Class, Applications, End use and Region.

Cancer Biologics Market: Drug Class Overview

In 2023, the global Cancer Biologics market saw significant growth, particularly in the Monoclonal Antibodies segment, which held a dominant 32.5% share. The Drug Class segment is separated into Monoclonal Antibodies, Cancer Growth Inhibitors, Vaccines, Recombinant Proteins, CAR-T Cells, Angiogenesis Inhibitors, Interleukins (IL), Interferons (IFN), Gene Therapy, and Others. Monoclonal antibodies, crafted in labs to mimic the immune systems infection-fighting abilities, are proving pivotal in cancer treatment. These biologics target specific proteins on cancer cells, hindering tumour growth, promoting immune-driven destruction, or delivering potent treatments directly to cancerous cells. Key examples like trastuzumab (Herceptin) for HER2-positive breast cancer and rituximab (Rituxan) for certain lymphomas have demonstrated impressive clinical efficacy and safety. The markets growth is fuelled by factors such as increasing cancer prevalence, advances in genomic research, and the accessibility of technologies for monoclonal antibody development, driving further innovation and market expansion.

Cancer Biologics Market: Applications Overview

In 2023, the global Cancer Biologics market witnessed significant growth, with Blood Cancer category dominating at a remarkable 26.7% share. The Applications segment is categorized into Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Gastric Cancer, Ovarian Cancer, Skin Cancer, Liver Cancer, and Others. Blood cancer, also called hematological malignancy, encompasses cancers impacting blood, bone marrow, and the lymphatic system. Varieties include leukemia, lymphoma, and multiple myeloma, each with distinct sub-types. This form of cancer involves abnormal cell proliferation in these areas, disrupting blood and immune system functions. The culmination of this growth results in the formation of cancer cells. This sectors significant growth reflects the pressing need for advanced treatments and therapies in addressing blood cancer, driving innovation and investment in the Cancer Biologics market.

Cancer Biologics Market: End use Overview

In 2023, the global Cancer Biologics market witnessed significant growth, especially in the Hospitals segment, which commanded a significant share of 61.1%. The End use segment is categorized into Hospitals, Cancer Centre, and Academics & Research Institutes. Hospitals consistently offer comprehensive oncology services, including treatment and ensuring the availability of biologics. Many hospitals actively participate in cancer research and clinical trials to adopt new biologics. They provide a range of cancer care services such as surgery, chemotherapy, diagnostics, and biological therapies. Moreover, reimbursement policies typically favour hospitals providing cancer care services, encouraging healthcare providers to offer Cancer Biologics within healthcare settings. This growth trend underscores the pivotal role of hospitals in advancing cancer treatment and underscores the importance of their contributions to the Cancer Biologics market.

Key Trends

1. Cancer Biologics is gaining traction in developing nations like India, China, and Brazil due to the increasing prevalence of cancer. Factors like large populations and growing elderly demographics are fueling healthcare sector growth, making these regions lucrative for pharmaceutical companies specializing in oncology drugs.
2. Patients are increasingly opting for biologic treatments due to their targeted approach, lower toxicity compared to traditional chemotherapy, and potential for longer-lasting results. This shift in consumer preference, alongside advancements in delivery methods and supportive care, is boosting the demand for biologic therapies in the Cancer Biologics Market.
3. The rising burden of cancer worldwide is a major driver of the Cancer Biologics Market. As cancer rates increase, theres a heightened demand for innovative treatment options like biologic therapies, which offer better outcomes for patients.
4. Ongoing progress in biotechnology is leading to the development of novel biological therapies for cancer treatment. These advancements include the discovery of new therapeutic targets, the creation of monoclonal antibodies, and the engineering of cell-based immunotherapies. Such innovations are driving market growth and expanding the application of biologic therapies across various cancer types, including breast cancer, lung cancer, colorectal cancer, and leukemia.

Premium Insights

The global Cancer Biologics market is experiencing remarkable growth due to rising demand for innovative treatments and biotechnology advancements. Biologic drugs from living organisms offer targeted therapies, including monoclonal antibodies, vaccines, cells, and recombinant proteins. Regulatory bodies like the FDA have approved numerous biologics; in 2023, the US FDA approved several new cancer drugs and biologic agents, including seven small-molecule inhibitors, four bispecific T cell engagers, two anti-PD-1 antibodies, and one cell therapy product. Clinical trials exploring treatments like adoptive cell transfer and immunotherapy are changing treatment approaches. Targeted therapies like angiogenesis inhibitors and CAR T-cell therapy are gaining traction. Monoclonal antibodies, growth factors, vaccines, and blood products dominate the market. Techniques like immunohistochemistry and next-generation sequencing support personalized medicine. Critical medications like Herceptin and Avastin are pivotal in cancer care. Collaborations with regulatory bodies ensure adherence to quality standards. The market promises better patient outcomes with advances in genomics and targeted therapy.

{{dashboard_image}}

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

The Cancer Biologics market encompasses drugs derived from living organisms to treat or prevent cancer. These biologics, such as monoclonal antibodies and cancer vaccines, offer targeted treatments with potentially fewer side effects compared to traditional chemotherapy. Factors driving market growth include the increasing incidence of cancer and advancements in biotechnology, such as next-generation sequencing and gene editing, enabling better understanding of genetic mutations driving cancer.

Pharmaceutical companies are investing heavily in research and development of biologics to meet the rising demand. However, concerns about side effects, including increased susceptibility to infections, pose a challenge to market expansion. For instance, individuals taking biologics may experience allergies or contract infections more easily, ranging from common respiratory infections to more serious conditions like tuberculosis and hepatitis B. Despite these challenges, rising awareness about the benefits of Cancer Biologics is expected to drive market growth in the coming years.

Competitive Landscape

Companies are adopting various strategies to strengthen their market position. These include forming strategic alliances and partnerships to leverage mutual strengths. Mergers and acquisitions are also common to enhance capabilities and market reach. Expanding into new geographical areas helps tap into emerging markets. Additionally, launching innovative products and services keeps companies competitive. Collaboration is crucial among healthcare providers, pharmaceutical companies, and regulatory agencies to overcome challenges and ensure a steady supply of biologics. Maintaining open communication and proactive partnerships enables effective information sharing, addresses supply chain issues, and simplifies regulatory processes, ensuring smooth market operations.

Recent Market Developments

• In January 2024, The European Commission approved Roches Tecentriq SC, the EUs first PD-L1 cancer immunotherapy subcutaneous injection for numerous cancer types.
• In January 2024, BioNTech and Duality Biologics announced that a Phase III study of the medicine for breast cancer had been initiated. BioNTech and Duality are conducting a Phase III study to evaluate their antibody-drug conjugate in patients whose tumours have low levels of progesterone or estrogen and respond to these hormones. This corresponds to between 40% and 45% of patients with metastatic breast cancer who are on Herceptin for HER2.
• In February 2024, Dupixent® sBLA was accepted for FDA priority review for treating COPD with type 2 inflammation.
• In March 2024, Novartis offered new evidence on the safety and efficacy of Zolgensma, including sustained and increased motor milestones in older and heavier children with SMA.
• In March 2024, Dr. Reddys Laboratories declared that Versavo® (bevacizumab) would be available in the UK. Avastins biosimilar Versavo is effective against multiple cancer types, such as advanced non-squamous non-small cell lung cancer, metastatic colorectal cancer, ovarian cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and metastatic breast cancer.